Latest Revenue Guidance News

SKS Technologies has reported a remarkable near doubling of revenue to $261.7 million in FY25, driven by strong growth in data centre projects and traditional markets. The company’s robust order book and expanded bank facilities position it well for continued growth in FY26.

Mader Group has delivered record FY25 results with revenue climbing 13% to $872.2 million and net profit rising 13%, setting the stage for a $1 billion revenue target in FY26.

Chrysos Corporation reported a robust FY25 with 46% revenue growth and an 80% jump in EBITDA, driven by expanding adoption of its PhotonAssay technology and a landmark contract with gold giant Newmont. The company projects further growth in FY26 with revenue guidance of $80-90 million.

Acusensus Limited reported a robust FY25 with 20% revenue growth and a significant 84% jump in total contract value, setting the stage for an ambitious FY26 forecast of up to 41% revenue increase.

Infomedia Ltd reported a solid FY25 with revenue up 4% and NPAT soaring 32%, while advancing AI initiatives and securing a takeover offer from TPG Capital.

Helia Group reports a robust 38% rise in statutory net profit for the first half of 2025, alongside a special dividend declaration, while navigating looming challenges from government policy shifts and lender contract changes.

Cogstate Limited has reported a landmark FY25 with revenue up 22% and net profit before tax nearly doubling, driven by a surge in clinical trials contracts and strategic innovation. The company also declared its maiden fully franked dividend and outlined ambitious growth plans including AI product launches and an expanding Medidata partnership.

NRW Holdings delivered a robust FY25 performance, posting a 12.2% revenue increase to $3.27 billion and securing a strong $6.1 billion order book. The company’s FY26 outlook remains positive with expected revenue growth and improved earnings.

Megaport Limited delivered a robust FY25 with 20% growth in annual recurring revenue and EBITDA surpassing guidance, setting the stage for continued expansion in FY26.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase in H1 2025, driven by strong sales of its precision medicine products and strategic acquisitions. The company is advancing multiple late-stage clinical trials and expanding its global manufacturing footprint.

Telix Pharmaceuticals reported a robust 63% revenue increase in H1 2025, driven by commercial growth and strategic investments, while advancing key clinical trials and maintaining full-year guidance.

Fisher & Paykel Healthcare has issued strong first half FY26 guidance, forecasting significant revenue and profit growth while navigating new US tariffs. Meanwhile, director Pip Greenwood announces her retirement after eight years on the board.